← FDA DRUG APPROVALS

FDA ANDA · ANDA070755

LITHIUM

Sponsor: PAI HOLDINGS PHARM

APPLICATION
ANDA070755
TYPE
ANDA
ORIGINAL APPROVAL
1986-05-21
LATEST ACTION
2022-10-13
ROUTE
ORAL
DOSAGE FORM
SYRUP
MARKETING STATUS
Prescription

Products

LITHIUM CITRATEPrescription
LITHIUM CITRATE EQ 300MG CARBONATE/5ML · SYRUP · ORAL

Approval history

2022-10-13Labeling · Supplement 15 · standardAP
2022-10-13Labeling · Supplement 14 · standardAP
2008-04-28Labeling · Supplement 13AP
1997-04-22Labeling · Supplement 9AP
1996-02-05Labeling · Supplement 8AP
1994-08-12Labeling · Supplement 7AP
1994-08-12Labeling · Supplement 18AP
1990-08-29Labeling · Supplement 6AP
1989-03-27Labeling · Supplement 5AP
1987-03-25Manufacturing (CMC) · Supplement 4AP
1987-03-25Manufacturing (CMC) · Supplement 3AP
1987-02-17Labeling · Supplement 2AP
1986-11-10Labeling · Supplement 1AP
1986-05-21OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →